Qulipta vs Aimovig
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Qulipta | US Aimovig | |
|---|---|---|
| Generic name | atogepant | erenumab |
| Drug class | CGRP Receptor Antagonist | CGRP Receptor Antagonist (Biologic) |
| Treats | Migraine prevention | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | Amgen/Novartis |
| Year approved | 2021 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | $100M |
| Common side effects | Nausea, Constipation, Fatigue, Decreased appetite | Constipation, Injection site reactions, Muscle cramps, High blood pressure |
Frequently asked questions
Is Qulipta or Aimovig better?
Neither is universally "better." Qulipta (atogepant) and Aimovig (erenumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Qulipta and Aimovig?
Qulipta is a CGRP Receptor Antagonist made by AbbVie, while Aimovig is a CGRP Receptor Antagonist (Biologic) made by Amgen/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Qulipta has the larger estimated TV advertising budget of the two.